 Connection
Vernon Holers to Autoimmune Diseases
This is a "connection" page, showing publications Vernon Holers has written about Autoimmune Diseases.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
3.304 |
|
|
|
-
Holers VM. Systemic lupus erythematosus as the paradigm for understanding the complex immune relationships and therapeutic opportunities for targeting complement in autoimmune diseases. Immunobiology. 2025 May; 230(3):152915.
Score: 0.731
-
Holers VM. Complement therapeutics are coming of age in rheumatology. Nat Rev Rheumatol. 2023 08; 19(8):470-485.
Score: 0.640
-
Thurman JM, Frazer-Abel A, Holers VM. The Evolving Landscape for Complement Therapeutics in Rheumatic and Autoimmune Diseases. Arthritis Rheumatol. 2017 11; 69(11):2102-2113.
Score: 0.432
-
Holers VM, Thurman JM. The alternative pathway of complement in disease: opportunities for therapeutic targeting. Mol Immunol. 2004 Jun; 41(2-3):147-52.
Score: 0.171
-
Mueller AA, Sasaki T, Keegan JW, Nguyen JP, Griffith A, Horisberger AM, Licata T, Fieg E, Cao Y, Elahee M, Marks KE, Simmons DP, Briere LC, Cobban LA, Pallais JC, High FA, Walker MA, Linnoila JJ, Sparks JA, Holers VM, Costenbader KH, Sweetser DA, Krier JB, Loscalzo J, Lederer JA, Rao DA. High-dimensional immunophenotyping reveals immune cell aberrations in patients with undiagnosed inflammatory and autoimmune diseases. J Clin Invest. 2023 12 15; 133(24).
Score: 0.166
-
Holers VM. The complement system as a therapeutic target in autoimmunity. Clin Immunol. 2003 Jun; 107(3):140-51.
Score: 0.160
-
Fahnoe KC, Liu F, Morgan JG, Ryan ST, Storek M, Stark EG, Taylor FR, Holers VM, Thurman JM, Wawersik S, Kalled SL, Violette SM. Development and Optimization of Bifunctional Fusion Proteins to Locally Modulate Complement Activation in Diseased Tissue. Front Immunol. 2022; 13:869725.
Score: 0.149
-
Slight-Webb S, Bourn RL, Holers VM, James JA. Shared and unique immune alterations in pre-clinical autoimmunity. Curr Opin Immunol. 2019 12; 61:60-68.
Score: 0.124
-
Hernandez G, Mills TS, Rabe JL, Chavez JS, Kuldanek S, Kirkpatrick G, Noetzli L, Jubair WK, Zanche M, Myers JR, Stevens BM, Fleenor CJ, Adane B, Dinarello CA, Ashton J, Jordan CT, Di Paola J, Hagman JR, Holers VM, Kuhn KA, Pietras EM. Pro-inflammatory cytokine blockade attenuates myeloid expansion in a murine model of rheumatoid arthritis. Haematologica. 2020 03; 105(3):585-597.
Score: 0.121
-
Stathopoulos P, Chastre A, Waters P, Irani S, Fichtner ML, Benotti ES, Guthridge JM, Seifert J, Nowak RJ, Buckner JH, Holers VM, James JA, Hafler DA, O'Connor KC. Autoantibodies against Neurologic Antigens in Nonneurologic Autoimmunity. J Immunol. 2019 04 15; 202(8):2210-2219.
Score: 0.119
-
Mihai S, Hirose M, Wang Y, Thurman JM, Holers VM, Morgan BP, K?hl J, Zillikens D, Ludwig RJ, Nimmerjahn F. Specific Inhibition of Complement Activation Significantly Ameliorates Autoimmune Blistering Disease in Mice. Front Immunol. 2018; 9:535.
Score: 0.111
-
Takahashi K, Kozono Y, Waldschmidt TJ, Berthiaume D, Quigg RJ, Baron A, Holers VM. Mouse complement receptors type 1 (CR1;CD35) and type 2 (CR2;CD21): expression on normal B cell subpopulations and decreased levels during the development of autoimmunity in MRL/lpr mice. J Immunol. 1997 Aug 01; 159(3):1557-69.
Score: 0.106
-
Holers VM, Hollis GF, Schwartz BD, Evans RJ, Strauss-Schoenberger J, Carel JC, Barney DL, Li B, Stafford-Hollis J, Lacy PE. Induction of peri-insulitis but not diabetes in islet transplants expressing a single foreign antigen. A multi-stage model of disease. J Immunol. 1993 Nov 01; 151(9):5041-52.
Score: 0.082
-
Looney RJ, Diamond B, Holers VM, Levesque MC, Moreland L, Nahm MH, St Clair EW. Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases. Clin Immunol. 2007 Jun; 123(3):235-43.
Score: 0.052
-
Carroll MC, Holers VM. Innate autoimmunity. Adv Immunol. 2005; 86:137-57.
Score: 0.045
-
Boackle SA, Holers VM. Role of complement in the development of autoimmunity. Curr Dir Autoimmun. 2003; 6:154-68.
Score: 0.039
-
Kozono Y, Kotzin BL, Holers VM. Resting B cells from New Zealand Black mice demonstrate a defect in apoptosis induction following surface IgM ligation. J Immunol. 1996 Jun 01; 156(11):4498-503.
Score: 0.025
-
Pappworth IY, Kulik L, Haluszczak C, Reuter JW, Holers VM, Marchbank KJ. Increased B cell deletion and significantly reduced auto-antibody titre due to premature expression of human complement receptor 2 (CR2, CD21). Mol Immunol. 2009 Mar; 46(6):1042-9.
Score: 0.015
-
Bao L, Haas M, Boackle SA, Kraus DM, Cunningham PN, Park P, Alexander JJ, Anderson RK, Culhane K, Holers VM, Quigg RJ. Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice. J Immunol. 2002 Apr 01; 168(7):3601-7.
Score: 0.009
-
Sekine H, Reilly CM, Molano ID, Garnier G, Circolo A, Ruiz P, Holers VM, Boackle SA, Gilkeson GS. Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice. J Immunol. 2001 May 15; 166(10):6444-51.
Score: 0.009
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|